Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from MEI Pharma ( (MEIP) ) is now available.
On July 22, 2025, MEI Pharma issued pre-funded warrants to purchase up to 6,022,869 shares of its Common Stock at $3.4199 per warrant in a private placement offering. By July 24, 2025, an investor exercised warrants to acquire 2,084,509 shares, paying $208.45 in cash, utilizing exemptions from registration under the Securities Act.
Spark’s Take on MEIP Stock
According to Spark, TipRanks’ AI Analyst, MEIP is a Neutral.
MEI Pharma’s overall stock score is low, primarily due to significant financial performance challenges and poor valuation metrics. Weak revenue and profitability, declining asset base, and negative cash flow contribute to a fragile financial position. Additionally, technical indicators suggest a bearish trend, further impacting investor sentiment. Without clear guidance or positive corporate events, the stock’s outlook remains unfavorable.
To see Spark’s full report on MEIP stock, click here.
More about MEI Pharma
Average Trading Volume: 982,228
Technical Sentiment Signal: Buy
Current Market Cap: $39.64M
See more data about MEIP stock on TipRanks’ Stock Analysis page.